Tenaya Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TNYA | LXEO | RNA | RCKT | BCDA | TENX | |
|---|---|---|---|---|---|---|
| Market cap | 84.31M | 265.14M | 148.48M | 286.51M | 13.82M | 67.74M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.9 | -2.4 | -1.5 | -1.6 | -1.6 | -1.2 |
| Price/book | 1.2 | 1.1 | 0.7 | 0.8 | 5.1 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −72.59% | −61.64% | −41.15% | −19.20% | −28.91% | −73.84% |
| Today | +2.66% | +3.86% | −0.46% | +3.98% | −0.92% | −1.63% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TNYA news ›Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint TN-201 Granted PRIME Designation by EMA; and Pediatric Indication…
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with…
Tenvie Therapeutics Announces First Subject Dosed in Phase 1 Trial of TNV313, Expanding Its Fully CNS-Penetrant NLRP3 Franchise
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
Reviewing Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC)
Posted by Tristan Rich on Oct 24th, 2026 Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) and C4 Therapeutics (NASDAQ:CCCC – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the…
Head-To-Head Survey: Kamada (NASDAQ:KMDA) and Tenaya Therapeutics (NASDAQ:TNYA)
Posted by Defense World Staff on Oct 19th, 2026 Kamada (NASDAQ:KMDA – Get Free Report) and Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two…
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages
Posted by Sarita Garza on Oct 7th, 2026 Several equities research analysts have recently commented on the stock. Wall Street Zen raised shares of Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a research report on…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com2
- biospace.com1
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.